Top barriers by category listed with their respective weighted ranked scores
| Drug development | Weighted Prioritisation Score |
| Lack of biomarkers to predict response to drug in clinical trials | 6.614 |
| Lack of user-friendly, sensitive and accurate outcome measures | 6.394 |
| Flawed clinical trial design | 6.370 |
| Challenges with collecting patient-reported and clinician-reported outcomes | 5.559 |
| Lack of alignment between patients, providers and regulatory | 5.370 |
| Challenges with attracting under-represented study populations | 5.173 |
| Limited awareness of lupus among non-expert medical professionals | 3.370 |
| Lack of attention to R&D paediatric issues | 3.173 |
| Lack of classification criteria | 2.976 |
| Clinical care | Weighted Prioritisation Score |
| Lack of diagnostic, predictive and prognostic biomarkers for lupus | 7.294 |
| Lack of treatment adherence | 6.717 |
| Limited awareness and understanding of lupus among non-expert medical professionals | 5.800 |
| Lack of clear risk factors that trigger lupus and lupus-like diseases (onset and flares) | 5.690 |
| Inadequate understanding of benefit-risk trade-offs between physicians and patients | 5.103 |
| Lack of attention to paediatric issues | 3.968 |
| Lack of diagnostic criteria | 3.873 |
| Access and value | Weighted Prioritisation Score |
| Barriers to effective management of lupus due to social determinants of care in predominantly lower socioeconomic status areas | 6.937 |
| Lack of access to clinicians familiar with lupus | 6.873 |
| Lack of access to medications either due to lack of coverage or added cost to patients | 6.492 |
| Lack of understanding by government payers/insurers about lupus and the medications needed to treat the disease | 5.976 |
| Lack of tools for collecting real world evidence | 4.089 |